David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 40,559 shares at $27.37 ($1.1M) on 2026-03-12, disclosed to the SEC on 2026-03-16.
Scheduled sale ($1.1M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.37 | 6,348 | $174K | 16.1% |
| 2 | $27.37 | 6,348 | $174K | 16.1% |
| 3 | $25.91 | 10,726 | $278K | 25.8% |
| 4 | $25.91 | 10,726 | $278K | 25.8% |
| 5 | $27.37 | 3,079 | $84K | 7.8% |
| 6 | $27.37 | 3,079 |
| $84K |
| 7.8% |
| 7 | $27.82 | 253 | $7K | 0.7% |
| Total | $26.60 avg | 40,559 | $1.1M | 100% |
| Filing → |
| MLYS | SELL | 2026-07-15 | $557K | — | Filing → |
| MLYS | SELL | 2026-07-10 | $66K | — | Filing → |
| MLYS | SELL | 2026-06-17 | $350K | — | Filing → |